After watching the stock price rise last week I knew someone had the Europe trial info. Truly amazing News. No I do not own the stock or any stock for that matter. I figured somthing was up with the activity.
Let's all pray that this one finally pans out. So many disappointments that eventually they HAVE to come up with something better than the current tx and it has to follow all the way through!
As a non-naive person it would not benefit me at this time but for those it would....GO BABY GO!
GO GO GO!
maybe I am missing something, but is this not basically the same data that was floating around before? extremely rapid viral load drop? I don't think anything really new has come out yet. It seems to still be Phase 1.
at least the stock talk is left out, ;-]
It does sound extremely hopeful, but until SVR data comes in, none of the new meds have a place in standard tx protocol.I am waiting for Phase III results, in ALL meds on trials, before getting excited.
one person's opinion
The 2-week period was completed quite some time ago. How come no info since them? Rebound? Rapid resistance?
Also on the horizon with much better data from a ongoing phase IIb trial without the thrombocytopenia and neutropenia safety issues VX950 has shown.
Idenix Pharmaceuticals Reports Positive 4-Week Data From A Phase IIb Clinical Trial Evaluating Valopicitabine (NM283) Combined with Pegylated Interferon in Treatment-Naive Hepatitis C Patients
SAN FRANCISCO, Jan 09, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced partial 4-week data today from an ongoing phase IIb clinical trial demonstrating that treatment with valopicitabine combined with pegylated interferon resulted in rapid and marked reduction in virus levels in treatment-naïve genotype 1 hepatitis C patients. The mean reduction in virus levels was greater than or equal to 4 log10, or 99.99 percent, after 4 weeks of treatment among patients in the two dose groups that began on Day 1 with 800 mg doses of valopicitabine. This trial is almost fully enrolled, with a target enrollment of 175 patients at more than 20 medical centers in the U.S. These partial data will be presented at the 24th Annual JP Morgan Healthcare Conference on Wednesday, January 11 at 2:00 p.m. (PST).
Just to give everyone a perspective to this news, the L.A. Times reported in October of last year that there were currently over 24 new HCV treatments in developement.
As another added note any new drugs were 3 to 5 years from being FDA approved. Peace
thanks for balancing the act,Andy, there are least two people here on that drug, one of them non responder and is now clear and doing very well. all I want to see is some balance. maybe is just me.